Switzerland’s Obseva eyes China re-start for fertility drug that failed trial | Reuters

ObsEva struck a pact with China’s Yuyuan BioScience Technology to develop and commercialize the fertility drug nolasiban, the Swiss drugmaker said on Monday as it seeks to inject new life into a medicine that had flopped a trial.

@ Reuters | January 13, 2020

China Moly takes full control of ex-Dreyfus metals unit for $518 million | Reuters

China Molybdenum Co, majority owner of a huge copper-cobalt mine in the Democratic Republic of Congo, said on Thursday it had completed the acquisition of all of IXM, formerly the metals business of trading house Louis Dreyfus, for $518 million.

@ Reuters | July 25, 2019